

Appendix 1

Table A1. Individual case dispositions. Cases in shaded row were positive for UC

Case					Cxbladder result	
study	Smoking					
no.	Gender	history	Age	Ethnicity	Triage setting	Detection setting
1	F	Smoker	84	Caucasian	PHYSICIAN-DIRECTED PROTOCOL	LOW
2	F	Ex-smoker	66	Caucasian	NEGATIVE	LOW
3	F	Ex-smoker	61	Caucasian	NEGATIVE	LOW
4	F	Non-smoker	79	Caucasian	PHYSICIAN-DIRECTED PROTOCOL	HIGH
5	F	Non-smoker	71	Caucasian	NEGATIVE	LOW
6*	F	Non-smoker	91	Asian/Indian	PHYSICIAN-DIRECTED PROTOCOL	HIGH
7	F	Non-smoker	72	Middle Eastern	NEGATIVE	LOW
8	M	Smoker	64	Caucasian	PHYSICIAN-DIRECTED PROTOCOL	LOW
9	M	Smoker	32	Asian/Indian	NEGATIVE	LOW
10	M	Ex-smoker	82	Caucasian	PHYSICIAN-DIRECTED PROTOCOL	LOW
11	M	Ex-smoker	64	Caucasian	PHYSICIAN-DIRECTED PROTOCOL	LOW
12†	M	Ex-smoker	69	Caucasian	PHYSICIAN-DIRECTED PROTOCOL	MEDIUM
13	M	Ex-smoker	63	Caucasian	PHYSICIAN-DIRECTED PROTOCOL	LOW
14	M	Ex-smoker	35	Middle Eastern	NEGATIVE	LOW
15	M	Ex-smoker	88	Asian/Indian	PHYSICIAN-DIRECTED PROTOCOL	LOW
16	M	Non-smoker	82	Caucasian	NEGATIVE	LOW
17	F	Non-smoker	54	NA	NEGATIVE	LOW
18	F	Non-smoker	83	NA	PHYSICIAN-DIRECTED PROTOCOL	LOW
19	F	Non-smoker	57	NA	NEGATIVE	LOW
20	M	Smoker	77	NA	NEGATIVE	LOW
21	M	Non-smoker	33	NA	NEGATIVE	LOW

22	F	Non-smoker	75	NA	NEGATIVE	LOW
23	F	Non-smoker	86	NA	NEGATIVE	LOW
24	M	Ex-smoker	68	NA	NEGATIVE	LOW
25	F	Non-smoker	37	NA	NEGATIVE	LOW
26	F	Non-smoker	34	NA	NEGATIVE	LOW
27	F	Non-smoker	55	NA	NEGATIVE	LOW
28	F	Non-smoker	33	NA	NEGATIVE	LOW
29	F	Non-smoker	75	Caucasian	NEGATIVE	LOW
30	F	Ex-smoker	50	Caucasian	NEGATIVE	LOW
31	M	Non-smoker	84	NA	NEGATIVE	LOW
32	F	Non-smoker	81	NA	PHYSICIAN-DIRECTED PROTOCOL	LOW
33	M	Non-smoker	68	NA	NEGATIVE	LOW

*High-grade Ta; †Low grade Ta

F, female; M, Male; NA, not available

Appendix 2

Below is a list of the urologists who acted as participating physicians during this study (in alphabetical order):

Lewis Chan (Concord Hospital, Sydney, NSW, AUSTRALIA)

Christopher Chemasle (Palmerston North Urology, Palmerston North, NEW ZEALAND)

Joe DiTrollo (Roseland, NJ, USA)

Sia Daneshmand (University of Southern California, Los Angeles, CA, USA)

Peter Gilling (Urology BOP, Tauranga, NEW ZEALAND)

Dennis Gyomber (John Fawcner Hospital Consulting Suites, Melbourne, VIC, AUSTRALIA)

Jonathan Masters (Auckland City Hospital, Auckland, NEW ZEALAND)

Scott Owens (Urology of Central Pennsylvania, Camp Hill, PA, USA)

Jay Raman (Penn State Milton S. Hershey Medical Center, Hershey, PA, USA)

Rod Studd (Southern Cross Hospital, Wellington, NEW ZEALAND)

James Sylora (Mid West Urologist, Evergreen Park, IL, USA)

Kian Tai (Tan Tock Seng Hospital Medical Centre, SINGAPORE)

Appendix 3

Figure A3. Number of patients with at least one invasive diagnostic test requested following primary evaluation. Dashed line represents the number of patients for whom at least one invasive diagnostic procedure was expected to have been requested (A); Change in the number of patients referred for invasive diagnostic procedures by individual participants after disclosure of Cxbladder results in both the Triage and Detect modalities (B). ○ and ○○ indicate where one or two cases of UC, respectively, would not have been referred for invasive diagnostics following primary evaluation. Note: all patients with UC would have been referred for an invasive test following disclosure of Cxbladder results.

